Westamerica Bancorporation Declares Quarterly Cash Dividend, Payable on May 15, 2026

Westamerica Bancorporation announced a quarterly cash dividend of $0.48 per share, marking a two-cent increase from the previous quarter. The dividend will be paid on May 15, 2026, to shareholders of record as of May 4, 2026. This announcement includes details on the company's recent financial results and its banking operations across Northern and Central California.

Original reporting
www.marketscreener.com · S&P Capital IQ
Published Apr 24, 2026, 2:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 24, 2026, 2:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$WABC
Bullish
high confidence
Mentioned
$WABC
Relevance
6/10
AlphAI data visualization · based on www.marketscreener.com
Decision brief

The 30-second read

$WABCBullishMed
01

Why it matters

The dividend increase signals confidence in future earnings, which may attract income-focused investors.

02

Market read

The news is highly relevant for regional banking investors and dividend-focused portfolios, with moderate impact on the local financial markets.

03

What to watch

Potential interest rate changes or regional economic shifts could impact bank profitability and stock performance.

Relevance 6/10Timing: Immediate, as the dividend payment date is set for May 15, 2026.

Background

Westamerica Bancorporation has demonstrated consistent financial performance, with recent results supporting a dividend hike.

Company-level read

Ticker impact

$WABCBullishHigh confidence
Context

High relevance due to the company's recent dividend increase and positive sentiment.

Expected impact

Moderate upward movement in WABC stock price over the short term, with potential for increased investor interest.

Evidence & confidence

The dividend hike indicates strong financial health, which typically attracts investors and can boost stock price. The positive sentiment score supports this outlook.

Market effects

Potential positive impact on regional banking sector stocks due to increased investor confidence.

Likely to bolster banking stocks in Northern and Central California regions.

Limited, as the news pertains to a regional bank with no immediate global implications.

Counterpoint

The dividend increase may already be priced in, and the stock could experience a pullback if broader market conditions deteriorate.

Key entities

  • Westamerica Bancorporation

    A regional bank operating in Northern and Central California.

Related articles

$WABCMed

Westamerica Bancorporation Reports Second Quarter 2026 Financial Results

WESTAMERICA BANCORPORATION (WABC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Westamerica Bancorporation Reports Second Quarter 2026 Financial Results SAN RAFAEL, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Westamerica Bancorporation (Nasdaq: WABC), parent company of Westamerica Bank, generated net

$WABCMedAI 9/10

Westamerica Bancorporation (NASDAQ:WABC) Hits New 12

Westamerica Bancorporation (NASDAQ:WABC) hit a new 52-week high on Tuesday, trading up to $56.24 and last at $56.18 versus a prior close of $55.36. The stock’s price targets include Keefe, Bruyette & Woods raising its target to $58.00. In its April 16 earnings, WABC reported $1.13 EPS and $62.08M revenue, and declared a $0.48 quarterly dividend.

$DAREMedAI 8/10

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

$MCDMed

Bernstein cuts McDonald’s stock price target on U.S. sales concerns

Bernstein lowered McDonald's (MCD) price target to $250 from $295, citing U.S. sales concerns and unproven upside from the Next menu. The stock is near its 52-week low, down 23% YTD. Bernstein projects 2% same-store sales growth and 2% net unit contribution. Other analysts have also revised earnings downwards, though some suggest the stock may be undervalued. McDonald's recently sold a Hong Kong store for $15.3 million.